Replies to post #5115 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA FY3Q25* results—>continued reduction in expenses:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-44

• 6/30/25 cash = $204.1M, an increase of $10.7M from 3/31/25 owing to a $33.4M tax refund received in April.

• FY3Q25 gross Mavyret royalty revenue was $18.3M, +2% QoQ, +2% YoY. Please see #msg-176510834 and #msg-176309105 for related info.

• FY3Q25 R&D expenses were $27.2M, -3% QoQ, -5% YoY.

• FY3Q25 SG&A expenses were $10.0M, -12% QoQ, -27% YoY.

• ENTA reiterated that its cash and expected royalty revenue are sufficient to fund operations “into FY2028,” which starts on 10/1/27.

*Fiscal year 2025 ends on 9/30/25.